A Randomized Double-blind Placebo-Controlled Study of Ibudilast for Treating Alcohol Use Disorder
Brief description of study
The goal of this is to evaluate the safety and effectiveness of the drug Ibudilast compared to placebo (an inactive pill) in reducing the number of drinking days and the amount of alcohol consumed by people who want to stop or reduce their drinking.
Study duration 11 weeks and includes 4 study visits.
Compensation upto $248.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research, Alcoholism
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
20 Mar 2024.
Study ID: 851593
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
